Announcement PDF +61 (03) 9482 3940 157 Heidelberg Rd, Northcote, VIC 3070 www.renerve.com.au ASX Announcement 3 December 2025 Correction to Notice of Meeting ReNerve Limited (ASX, "ReNerve" or "the Company"), refers to the Notice of Meeting to be held on Monday 5 January at 10.00am (AEDT) virtually released with the ASX on 2 December 2025. The Company wishes to correct the section on page 2 under “Meeting Attendance” per the following: MEETING ATTENDANCE Shareholders who wish to attend the meeting in person are requested to notify and register their attendance with the Company at info@renerve.com.au. Shareholders do not need to attend the Meeting to cast their vote/s and are encouraged to submit their votes and appoint the Chairperson as their proxy. Detailed instructions for lodging votes and appointment of a proxy are included in the accompanying Notice of Meeting and Proxy Form. This should state: VENUE AND VOTING INFORMATION The company is pleased to provide shareholders with the opportunity to attend and participate in a virtual Meeting through an online meeting platform powered by Automic. Shareholders that have an existing account with Automic will be able to watch, listen and vote online. Shareholders who do not have an account with Automic are strongly encouraged to register for an account as soon as possible and well in advance of the Meeting to avoid any delays on the day of the Meeting. An account can be created via the following link investor.automic.com.au and then clicking on “register” and following the prompts. Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic. To access the virtual meeting on the day: 1. Open your internet browser and go to investor.automic.com.au 2. Login with your username and password or click “register” if you haven’t already created an account. Shareholders are encouraged to create an account prior to the start of the meeting to ensure there is no delay in attending the virtual meeting 3. After logging in, a banner will display at the bottom of your screen to indicate that the meeting is open for registration, click on “Register” when this appears. Alternatively, click on “Meetings” on the left-hand menu bar to join the meeting. 4. Click on “Join Meeting” and follow the prompts om screen to register and vote. 2 | P a g e Shareholders will be able to vote (see the “Voting virtually at the Meeting” section of this Notice of Meeting below) and ask questions at the virtual meeting. Shareholders are also encouraged to submit questions in advance of the Meeting to the Company. Questions must be submitted in writing to info@careteq.com.au at least 48 hours before the GM The Company will also provide Shareholders with the opportunity to ask questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its business. Voting virtually at the Meeting Shareholders who wish to vote virtually on the day of the GM can do so by logging in to the Automic shareholder portal. 1. Open your internet browser and go to investor.automic.com.au 2. Login using your username and password. If you do not already have an account, click “Register” and follow the prompts. Shareholders are encouraged to register prior to the commencement of the Meeting to avoid delays in accessing the virtual platform. 3. After logging in, a banner will appear at the bottom of your screen when the Meeting is open for registration. Click “Register”. Alternatively, select Meetings from the left-hand menu. 4. Click on “Join Meeting” and follow the prompts. 5. When the Chair of the Meeting declares the poll open, select the “Voting” dropdown menu on the right-hand side of your screen . 6. Select either the “Full” or “Allocate” option to access your electronic voting card. 7. Follow the prompts to record your voting direction for each resolution and click “Submit votes”. For allocated votes, the number of votes submitted must not exceed your remaining available units. Important: Votes cannot be amended once submitted. For further information on the live voting process please see the Registration and Voting Guide at https://www.automicgroup.com.au/virtual-GMs/ It is recommended that Shareholders wishing to attend the Meeting login 30 mins before the meeting on 5 January 2026. Shareholders do not need to attend the Meeting to cast their vote/s and are encouraged to submit their votes and appoint the Chairperson as their proxy. Detailed instructions for lodging votes and appointment of a proxy are included in the accompanying Notice of Meeting and Proxy Form. Voting on all Resolutions at the Meeting will be conducted by poll. Please refer the to the updated Notice of General Meeting and Proxy Form accompanying this announcement. - ENDS - This announcement has been approved for release by the Company’s Board of Directors. 3 | P a g e For further information and enquiries, please contact: Dr Julian Chick CEO & Managing Director ReNerve Ltd +61 (03) 9482 3940 info@renerve.com.au Matthew Wright Investor & Media Relations NWR Communications +61 (0) 451 896 420 matt@nwrcommunications.com.au About ReNerve Limited (ASX:RNV) ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide. Proven Clinical Success ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives. Comprehensive Product Portfolio ReNerve is advancing a complete suite of nerve repair solutions: • NervAlign® Nerve Cuff – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery. • Deep Dermal tissue product -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases. • Amniotic tissue product ranges -- Three amniotic tissue product ranges used to aid the healing of wounds. • NervAlign® Nerve Conduit Range – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends. • NervAlign® Nerve Guide Matrix – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting. • NervAlign® Bionic Nerve – Next-generation combination technology for the most challenging nerve repairs. 4 | P a g e Market Leadership and Growth With demonstrated market traction since the Company’s 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.1 Vision and Values We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery. 1 Global Nerve Repair Biomaterials Market Research Report (2020 – 2031) Page 1 RENERVE LIMITED ACN 614 848 216 Notice of General Meeting Explanatory Memorandum & Proxy Form Notice is given that the Meeting will be held at: DATE: Monday 5 January 2026 TIME: 10.00AM (AEDT) VENUE: Held as a Virtual Meeting The business of Meeting affects your shareholding and your vote is important. This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting. Page 2 RENERVE LIMITED Notice of General Meeting Notice is given that the 2026 General Meeting of the Shareholders of ReNerve Limited (ACN 614 848 216) (ReNerve or the Company) will be Monday 5 January at 10.00am (AEDT) virtually. Shareholders are strongly encouraged to submit their proxies as early as possible and in any event prior to the cut- off for proxy voting as set out in the Notice. To lodge your proxy, please follow the directions on your personalised proxy form which will be enclosed with a copy of the Notice, delivered to you by email or post (depending on your communication preferences). If a Shareholder has nominated for electronic communications, they will receive the Notice by email. Other Shareholders will receive a postcard with a URL link to the Notice and Proxy Form. VENUE AND VOTING INFORMATION The company is pleased to provide shareholders with the opportunity to attend and participate in a virtual Meeting through an online meeting platform powered by Automic. Shareholders that have an existing account with Automic will be able to watch, listen and vote online. Shareholders who do not have an account with Automic are strongly encouraged to register for an account as soon as possible and well in advance of the Meeting to avoid any delays on the day of the Meeting. An account can be created via the following link investor.automic.com.au and then clicking on “register” and following the prompts. Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic. To access the virtual meeting on the day: 1. Open your internet browser and go to investor.automic.com.au 2. Login with your username and password or click “register” if you haven’t already created an account. Shareholders are encouraged to create an account prior to the start of the meeting to ensure there is no delay in attending the virtual meeting 3. After logging in, a banner will display at the bottom of your screen to indicate that the meeting is open for registration, click on “Register” when this appears. Alternatively, click on “Meetings” on the left-hand menu bar to join the meeting. 4. Click on “Join Meeting” and follow the prompts om screen to register and vote. Shareholders will be able to vote (see the “Voting virtually at the Meeting” section of this Notice of Meeting below) and ask questions at the virtual meeting. Shareholders are also encouraged to submit questions in advance of the Meeting to the Company. Questions must be submitted in writing to info@careteq.com.au at least 48 hours before the GM The Company will also provide Shareholders with the opportunity to ask questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its business. Voting virtually at the Meeting Shareholders who wish to vote virtually on the day of the GM can do so by logging in to the Automic shareholder portal. 1. Open your internet browser and go to investor.automic.com.au 2. Login using your username and password. If you do not already have an account, click “Register” and follow the prompts. Shareholders are encouraged to register prior to the commencement of the Meeting to avoid delays in accessing the virtual platform. 3. After logging in, a banner will appear at the bottom of your screen when the Meeting is open for registration. Click “Register”. Alternatively, select Meetings from the left-hand menu. 4. Click on “Join Meeting” and follow the prompts. 5. When the Chair of the Meeting declares the poll open, select the “Voting” dropdown menu on the right- hand side of your screen . 6. Select either the “Full” or “Allocate” option to access your electronic voting card. Page 3 VOTING ELIGIBILITY The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Act 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 10.00am AEDT on 1 January 2026. If you have any queries on how to cast your votes, please email Automic at: meetings@automicgroup.com.au. VOTING BY ATTORNEY Shareholders intending to attend the Meeting by attorney must ensure that they have provided the original or a certified copy of the power of attorney to the Company, in the same manner prescribed below for the giving of proxy forms to the Company. VOTING BY PROXY To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form. In accordance with section 249L of the Corporations Act, Shareholders are advised that: • each Shareholder has a right to appoint a proxy; • the proxy need not be a Shareholder; and • a Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the member appoints two proxies and the appointment does not specify the proportion or number of the member’s votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes. Proxy vote if appointment specifies way to vote Section 250BB(1) of the Corporations Act provides that an appointment of a proxy may specify the way the proxy is to vote on a particular Resolution. If an appointment of a proxy specifies the way the proxy is to vote on a particular Resolution: • The proxy need not vote on a show of hands, but if the proxy does so, the proxy must vote that way (i.e. as directed); and • If the proxy has two or more appointments that specify different ways to vote on the Resolution, the proxy must not vote on a show of hands; and • If the proxy is the Chair at which the Resolution is voted on, the proxy must vote on a poll, and must vote that way (i.e. as directed); and • If the proxy is not the Chair, the proxy need not vote on the poll, but if the proxy does so, the proxy must vote that way (i.e. as directed); and If the proxy is not the Chair and at the Meeting, a poll is duly demanded on the Resolution and either of the following applies: Voting on all Resolutions at the Meeting will be conducted by poll. included in the accompanying Notice of Meeting and Proxy Form. appoint the Chairperson as their proxy. Detailed instructions for lodging votes and appointment of a proxy are Shareholders do not need to attend the Meeting to cast their vote/s and are encouraged to submit their votes and 2026. It is recommended that Shareholders wishing to attend the Meeting login 15 mins before the meeting on 5 January https://www.automicgroup.com.au/virtual-GMs/ For further information on the live voting process please see the Registration and Voting Guide at Votes cannot be amended once submitted. allocated votes, the number of votes submitted must not exceed your remaining available units. Important: Follow the prompts to record your voting direction for each resolution and click “Submit votes”. For 7. Page 4 CORPORATE REPRESENTATIVES A Shareholder that is a body corporate may appoint an individual to act as its representative at the Meeting by providing a duly executed Certificate of Appointment of Corporate Representative (Certificate). Unless otherwise specified in the Certificate, the representative may exercise all or any of the powers that the body corporate may exercise at the Meeting or in voting on a Resolution. A Certificate is available upon request from Automic. Certificates must be lodged in advance of the Meeting with Automic no less than 24 hours prior to the Meeting. QUESTIONS AND COMMENTS BY SHAREHOLDERS AT THE GENERAL MEETING In accordance with the Corporations Act, a reasonable opportunity will be given to Shareholders to ask questions about or make comments on the management of the Company at the Meeting. Shareholders may submit any written questions addressed to the Company via the address on the proxy form or to ReNerve Limited via email at info@renerve.com.au no later than 48 hours prior to the Meeting. The Company will either answer the questions at the Meeting or table written answers to them at the Meeting. If written answers are tabled at the Meeting, they will be made available to Shareholders as soon as practicable after the Meeting. Shareholders may also submit questions to the Board related to any of the resolutions to be considered. These questions will be responded to by the Board during the Meeting. As above, questions should be submitted to info@renerve.com.au no later than 48 hours prior to the Meeting. ENQUIRIES Shareholders are asked to contact the Company at info@renerve.com.au or the Company Secretary at david.lilja@dlkadvisory.com.au or on +61 3 9923 1222 if they have any queries in respect of the matters set out in these documents. The Chair intends to vote undirected proxies in favour of Resolutions 1 – 4. voting on the Resolutions. If you appoint the Chair of the Meeting as your proxy, you can direct the Chair to vote for or against or abstain from voting on the Resolution of the Meeting. the Chair is taken, before voting on the Resolution closes, to have been appointed as the proxy for the purposes of • the proxy does not vote on the Resolution, • the proxy is not recorded as attending the Meeting; or Page 5 RENERVE LIMITED Notice of General Meeting Notice is given that the 2026 General Meeting of the Shareholders of ReNerve Limited (ACN 614 848 216) (ReNerve or the Company) will be held on Monday 5 January 2026 at 10.00am (AEDT) virtually. The Explanatory Memorandum to this Notice of Meeting (Notice) provides additional information on matters to be considered at the General Meeting. The Explanatory Memorandum and the Proxy Form are part of this Notice. ORDINARY BUSINESS RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF 21,581,587 TRANCHE 1 PLACEMENT SHARES To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 21,581,587 Tranche 1 Placement Shares, on the terms and conditions specified in the Explanatory Memorandum which accompanies and forms part of this Notice.” A voting exclusion statement applies to this Resolution. RESOLUTION 2 – APPROVAL TO ISSUE 5,085,080 TRANCHE 2 PLACEMENT SHARES To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of 5,085,080 Tranche 2 Placement Shares, on the terms and conditions specified in the Explanatory Memorandum which accompanies and forms part of this Notice.” A voting exclusion statement applies to this Resolution. RESOLUTION 3 – APPROVAL TO ISSUE 26,666,667 ONE FOR ONE FREE ATTACHING OPTIONS To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of 26,666,667 Attaching Options, on the terms and conditions specified in the Explanatory Memorandum which accompanies and forms part of this Notice.” A voting exclusion statement applies to this Resolution. RESOLUTION 4 – APPROVAL TO ISSUE 4,000,000 LEAD MANAGER OPTIONS To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of 4,000,000 Joint Lead Manager Options, on the terms and conditions specified in the Explanatory Memorandum which accompanies and forms part of this Notice.” A voting exclusion statement applies to this Resolution. Page 6 VOTING EXCLUSIONS 1. Under the Corporations Act and ASX Listing Rule 14.11, the Company will disregard any votes cast in favour of the resolutions by or on behalf of: • the names person or class of persons excluded from voting as set out in the Explanatory Statement; or • an associate of that person or those persons. However, this does not apply to a vote cast in favour of a resolution by: • a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or • the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the chair to vote on the resolution as the chair decides; or • a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met. o the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of the person excluded from voting, on the resolution; and o the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way. 2. KMP that may have a vested interest in the outcome of a Resolution have restrictions on voting on those Resolutions. KMP include members of the Board and certain senior executives, as set out in the RNV Annual Report. The Corporations Act restricts KMP and their Closely Related Parties from voting in certain circumstances. 3. Under the Corporations and ASX Listing Rules, voting exclusions apply to the following Resolutions and further detail is provided in the Explanatory Statement: • Resolution 1 – Ratification of Prior Issue of 21,581,587 Tranche 1 Placement Shares; • Resolution 2 – Approval to Issue 5,085,080 Tranche 2 Placement Shares; • Resolution 3 – Approval to Issue 26,666,667 one for one free Attaching Options; and • Resolution 4 – Approval to Issue 4,000,000 Lead Manager Options. DATE: 2 December 2025 BY ORDER OF THE BOARD DAVID LILJA COMPANY SECRETARY Page 7 EXPLANATORY MEMORANDUM This Explanatory Memorandum has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions. RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF 21,581,587 TRANCHE 1 PLACEMENT SHARES 1.1 General As announced to the ASX on 20 November 2025 the Company completed a capital raising to new and existing professional and sophisticated investors, to raise approximately $3,200,000 (before costs) (Placement) by the issuance of 26,666,667 new shares (Placement Shares) via two tranches. The Placement comprises two tranches: • Tranche one raised $2,589,790 (before costs) and was made within the Company’s capacity under ASX Listing Rule 7.1 (21,581,587 Shares) (“Tranche 1 Placement Shares”) (“Tranche 1 Placement”). • Tranche two raised $610,209 (before costs) and is subject to shareholder approval per Resolution 2 below (5,085,080 Shares) (“Tranche 2 Placement Shares”) (“Tranche 2 Placement”). • The 26,666,667 Placement Shares were issued (in respect of the Tranche 1 Placement Shares) and are to be issued (in respect of the Tranche 2 Placement Shares) with a one for one free attaching option (“Attaching Options”) with an exercise price of $0.18 and a maturity date of two years from the date of issue, subject to shareholder approval per Resolution 3 below (“Attaching Options”). The Placement represented a 22.6% discount to the last closing price of the Company’s shares on 17 November 2025 and a 28.2% discount to the 15-day VWAP. ASX Listing Rule 7.1 limits the number of equity securities that a company may issue without member approval to 15% of the issued capital of the Company in any 12-month period (subject to certain exceptions). ASX Listing Rule 7.4 allows an issue of securities to be subsequently approved by shareholders and treated as having been made with approval of shareholders for the purpose of ASX Listing Rule 7.1. The Company is seeking subsequent shareholder approval of the issue of the Tranche 1 Placement Shares pursuant to ASX Listing Rule 7.4. All of the Tranche 1 Placement Shares being the subject of this resolution are ordinary fully paid shares which rank equally with all of the Company’s existing ordinary fully paid shares and are quoted on the ASX. The Tranche 1 Placement Shares were issued at A$0.12 per share. 1.2 Technical Information required by Listing Rule 14.1A If Resolution 1 is passed, the Tranche 1 Placement Shares will be excluded in calculating the Company’s 15% limit in ASX Listing Rule 7.1, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12-month period following the date of issue of the Tranche 1 Placement Shares. If Resolution 1 is not passed, the Tranche 1 Placement Shares will be included in calculating the Company’s 15% limit in ASX Listing Rule 7.1, effectively decreasing the number of equity securities that the Company can issue without shareholder approval over the 12-month period following the date of issue of the Tranche 1 Placement Shares. Page 8 Information required by Listing Rule 7.5 Pursuant to and in accordance with ASX Listing Rule 7.5, the following information is provided in relation to Resolution 1: • the Tranche 1 Placement Shares were issued to professional and sophisticated investors. The recipients were identified through a bookbuild process, which involved Alpine Capital Pty Ltd (Alpine) and SP Corporate Advisory Pty Ltd (Spark Plus) seeking expressions of interest to participate in the capital raising from non-related parties of the Company; • 21,581,587 Tranche 1 Placement Shares were issued and the Tranche 1 Placement Shares issued were all fully paid ordinary shares in the capital of the Company issued under the same terms and conditions as the Company’s existing Shares; • the Tranche 1 Placement Shares were issued 1 December 2025; • the issue price was $0.12 per share. The Company has not and will not receive any other consideration for the issue of the Tranche 1 Placement Shares; • the purpose of the issue was to raise capital to fund: - acceleration of the sales and marketing programmes for the Company's product lines already on market, the NervAlign® Nerve Cuff and EmpliQ ranges; - ongoing development of new products that the Company is planning to bring to market, including its range of nerve conduit products and its nerve guide matrix product; - strengthening of the Company’s sales team; and - working capital. • the Tranche 1 Placement Shares were not issued under an agreement. Voting Exclusion Statement In accordance with the Listing Rules, the Company will disregard any votes cast in favour of the Resolution 1 by or on behalf of a person or persons who participated in the Placement or is counterparty to the agreement being approved (namely those who participated in the Placement) or an associate if that person or those persons. However, this does not apply to a vote cast in favour of a resolution by: • a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or • the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the chair to vote on the resolution as the chair decides; or • a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met. - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of the person excluded from voting, on the resolution; and - the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way. RESOLUTION 2 – APPROVAL TO ISSUE 5,085,080 TRANCHE 2 PLACEMENT SHARES 2.1 General As noted at Resolution 1, the Company announced the Placement to the ASX on 20 November 2025, and this resolution seeks the approval to the issue of 5,085,080 new fully paid ordinary shares in relation to the Tranche 2 Placement that raised $610,209 before costs (the “Tranche 2 Placement”). The Placement represented a 22.6% discount to the last closing price of the Company’s shares on 17 November 2025 and a 28.2% discount to the 15-day VWAP. ASX Listing Rule 7.1 limits the number of equity securities that a company may issue without member approval to 15% of the issued capital of the Company in any 12-month period (subject to certain exceptions). Page 9 All of the Tranche 2Placement Shares being the subject of this resolution are ordinary fully paid shares which rank equally with all of the Company’s existing ordinary fully paid shares and are quoted on the ASX. The Placement Shares will be issued at A$0.12 per share. 2.2 Technical information required by Listing Rule 14.1A If Resolution 2 is passed, the Tranche 2 Placement Shares will be excluded in calculating the Company’s 15% limit in ASX Listing Rule 7.1, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12-month period following the date of issue of the Tranche 2Placement Shares. If Resolution 2 is not passed, the Tranche 2 Placement Shares will be included in calculating the Com